Investors Join Inclinix with PMG Research to create Global Clinical Trial Site and Patient Recruitment Organization, Inclinix-PMG Holdings
A consortium of investors led by Frontier Capital has funded the strategic merger of Inclinix with PMG Research, creating an organization designed to accelerate clinical trial enrollment from beginning to end. The company will be led by J. Tobin Geatz, President and CEO, and Jeffrey Reiniche, CFO.
"This novel business combination will allow sponsors and CROs to bundle the two most important services in a trial: world class sites and patient recruiting," noted Geatz. "We will have more than 120 Principal Investigators and 80 study coordinators, who together with Inclinix's 75+ global Clinical Enrollment Managers, provide our customers rapid enrollment locally and worldwide," he continued.
The company will operate in the short term as two divisions.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
